Healthy Skepticism Library
Items published during the years 1990 to 1999
There are 2138 items in the Healthy Skepticism Library that were published during the years 1990 to 1999.
Page 2 of 22 pages < 1 2 3 4 > Last ›
HSL2012
Galewitz P.
Study: Drugmaker Ads Can Backfire
AP Business Writer 1999 Jun 17
HSL6866
Lexchin J.
PMAC code of marketing practices.
CMAJ 1999 Jun 1; 160:(11):1556
http://www.cma.ca/cmaj/vol-160/issue-11/letters-11.htm#7
HSL16735
Wolfe S, Sasich L
The Wild, Wild Web
The Washington Post 1999 Jun 1
HSL236
Williams AH, Rowell M.
Private enterprise and public good: ethical issues in the funding of clinical research.
Ann R Coll Physicians Surg Can 1999 Jun; 32:(4):227-31
HSL2056
Bell RA, Wilkes MS, Kravitz RL.
Advertisement-induced prescription drug requests: patients' anticipated reactions to a physician who refuses.
J Fam Pract 1999 Jun; 48:(6):446-52
HSL6899
Lexchin J.
Re: the promotion of Atrovent (ipratropium bromide)
1999 Jun;
HSL7936
Smith D.
Who says consumers can't make decisions?
Pharmaceutical Executive 1999 Jun; 19:19
HSL7937
Prince R.
Generic firms seek government help to fight manufacturers for drug marketing rights
Pharmacy Practice News 1999 Jun; 26:1, 16
HSL7938
West D.
Crop at the top: popular ad shops of the DTC world
Pharmaceutical Executive 1999 Jun; 19:6-8, 10, 12, 14
HSL7939
Wechsler J.
Risky business
Pharmaceutical Executive 1999 Jun; 19:3
HSL8140
Rolland PD, Kablinger AS.
Recruitment for clinical trials: psychopharmacology research clinic's experience in recruiting for depression studies
ASHP Annual Meeting 1999 Jun; 56:
HSL8141
Hatwig CA, Ritz P, Nunan R, Ferer M, Dunwoody C.
Designing and implementing a public relations campaign for pharmacists
ASHP Annual Meeting 1999 Jun; 56:
HSL6873
Mansour P.
More lessons from unfortunate events in Toronto.
Lancet 1999 May 29; 353:(9167):1888
HSL7965
Bremer S.
Let the good times roll
Chemist and Druggist 1999 May 29; 251:16, 18, 20
HSL16736
Wolfe S, Lurie P
Comments in correspondence section in response to article entitled 'Science, ethics, and future of research into maternal-infant transmission of HIV-1'
The Lancet 1999 May 29; 353:9167
HSL6846
Donohoe MT, Matthews H.
Wasted paper in pharmaceutical samples.
N Engl J Med 1999 May 20; 340:(20):1600
HSL6844
Dieppe P, Chard J, Tallon D, Egger M.
Funding clinical research.
Lancet 1999 May 8; 353:(9164):1626
HSL14667
Does continuing medical education in general practice make a difference?
Cantillon P, Jones R
BMJ 1999 May 8; 318:(7193):1276-9
http://www.bmj.com/cgi/content/full/318/7193/1276
HSL5300
Chan DH, Leclair K, Kaczorowski J.
Problem-based small-group learning via the Internet among community family physicians: a randomized controlled trial.
MD Comput 1999 May-Jun 01; 16:(3):54-8
HSL6865
Lexchin J.
How patient outcomes are reported in drug advertisements.
Can Fam Physician 1999 May; 45:1213-6:
HSL6896
Dr. Celebrity
Consumer Reports 1999 May8-9
HSL6897
Molloy DW, Smith SD, Jubelis RM.
The Ideal Detail Program - comprehensive, up-to-date drug detailing
Health Law in Canada 1999 May; 19:(4):89-95
HSL6898
Paytash CA.
The learned intermediary doctrine and patient package inserts: a balanced approach to preventing drug-related injury.
Stanford Law Rev 1999 May; 51:(5):1343-71
HSL7942
West D.
Sensitivity training
Pharmaceutical Executive 1999 May; 19:
HSL7955
Smith DL.
Your patient package insert: does it help or hinder?
Pharmaceutical Executive 1999 May; 19:
HSL7962
West D.
Remote control? DTC ponders the twilight zone of TV advertising
Pharmaceutical Executive 1999 May; 19:
HSL7963
Wechsler J.
Regulating the Internet
Pharmaceutical Executive 1999 May; 19:
HSL11580
Lee TH.
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. What constitutes a useful economic study? The health systems perspective.
Am Heart J. 1999 May; 137:(5):S67-70
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=10220600
HSL18779
Hanson JD, Kysar DA.
Taking behavioralism seriously: some evidence of market manipulation
Harv Law Rev. 1999 May; 112:(7):1420-572.
http://www.ncbi.nlm.nih.gov/pubmed/10558427
HSL2341
Wang TJ, Ausiello JC, Stafford RS.
Trends in antihypertensive drug advertising, 1985-1996.
Circulation 1999 Apr 20; 99:(15):2055-7
http://circ.ahajournals.org/cgi/reprint/99/15/2055
HSL8099
Conlan MF.
Hot issues
Drug Topics 1999 Apr 19; 143:80-82, 84, 87, 89
HSL8124
APhA sets policy on telepharmacy, DTC ads, unions
American Journal of Health System Pharmacy 1999 Apr 15; 56:706-707
HSL6895
Working Group on Women and Health Protection
To do no harm: DTC advertising of prescription drugs
1999 Apr 12
www.hc-sc.gc.ca/hpb-dgps/therapeut/htmleng/consult_dtca.html
HSL2010
Schonhofer PS
Dipyrone (Metamizol): Restored to good repute?
Internistische Praxis 1999 Apr 0939:184-185
http://www.essentialdrugs.org/edrug/archive/199904/msg00014.php
HSL3689
Health Products and Food Branch, Health Canada.
Direct-to-consumer advertising of prescription drugs. [discussion document].
: Health Products and Food Branch, Health Canada. 1999 Apr 6
!www.hc-sc.gc.ca/hpfb-dgpsa/oria-bari/99-04-14_3_e.html.
HSL6894
Therapeutic Products Programme
Discussion document: direct-to-consumer advertising of prescription drugs
1999 Apr 6
www.hc-sc.gc.ca/hpb-dgps/therapeut/htmleng/consult_dtca.html
HSL6889
Leach B.
Marketing forces
The Health Exchange 1999 Apr8-9
HSL6892
Pharmaceutical Manufacturers Association of Canada
Advertising of prescription medicines to Canadian consumers: PMAC’s position
Ottawa: Pharmaceutical Manufacturers Association of Canada 1999 Apr
www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/consult/wkshd2ca.zip www.canadapharma.org/special-report/adv-position/Advertising-DTC.html
HSL6893
Hayes L, Smith D.
Drug industry sponsorship: at what price?
HAI News 1999 Apr; (106):1-2, 15-16
HSL7974
Nolan A.
Issues & priorities for the pharmaceutical industry in Ireland
Irish Pharmacy Journal 1999 Apr; 77:112-114
HSL8097
Buckley B.
Prescriptions grow 7% to 2.4 billion; sales increase 16% to $94 billion
Pharmacy Times 1999 Apr; 65:16-18, 21-22
HSL18022
Mangione-Smith R, McGlynn EA, Elliott MN, Krogstad P, Brook RH.
The relationship between perceived parental expectations and pediatrician antimicrobial prescribing behavior.
Pediatrics 1999 Apr; 103:(4):
http://pediatrics.aappublications.org/cgi/content/full/103/4/711
HSL19393
Rizzo JA
Advertising and competition in the ethical pharmaceutical industry: the case of antihypertensive drugs
J Law Econ 1999 Apr; 42:(1):89–116
http://ideas.repec.org/a/ucp/jlawec/v42y1999i1p89-116.html
HSL2011
Ragg M.
Capsule or pill, don't swallow it whole
Weekend Australian 1999 Mar 27
HSL18021
Murphy JE.
Generic substitution and optimal patient care.
Arch Intern Med 1999 Mar 8; 159:(5):429-33
http://archinte.ama-assn.org/cgi/content/full/159/5/429
HSL6875
Nathan DG, Weatherall DJ.
Academia and industry: lessons from the unfortunate events in Toronto.
Lancet 1999 Mar 6; 353:(9155):771-2
http://linkinghub.elsevier.com/retrieve/pii/S0140673699000720
HSL1824
Razack S, Arbour L, Hutcheon R.
Proposed model for interaction between residents and residency training programs, and pharmaceutical industry.
Ann R Coll Physicians Surg Can 1999 Mar; 32:(2):93-6
HSL6890
Law J.
Who will be the new voice of patients?
Scrip Magazine 1999 Mar30-33
www.pjbpubs.co.uk/scrip/scrhome.html
HSL6891
Memoirs of methods used to sell drugs
MaLAM International News 1999 Mar-Apr; 17:(3-4):1-6
HSL7968
Kravetz S.
Pharmacy profession unites to endorse collaborative drug therapy management
Pharmacy Practice News 1999 Mar; 26:10, 18
HSL7969
Wilcock M.
Take the heat out of prescribing
Pharmacy in Practice 1999 Mar; 9:86-87
HSL7973
Bloom MZ.
Direct-to-consumer advertising provides challenge to managed care
Journal-of-Managed-Care-Pharmacy 1999 Mar-Apr; 5:101-103, 106
HSL8123
Wechsler J.
Taking steps toward harmonization with Europe and Japan
Pharmaceutical Technology 1999 Mar; 23:16, 18, 20-22, 24, 26, 28, 30
HSL8139
Consumers want details about prescription drugs; many use alternative medicines
American Journal of Health System Pharmacy 1999 Feb 15; 56:307
HSL238
Wahlbeck K, Adams C.
Beyond conflict of interest: Sponsored drug trials show more-favourable outcomes.
BMJ 1999 Feb 13; 318:(7181):465
HSL239
Shuchman M.
Independent review adds to controversy at Sick Kids.
CMAJ 1999 Feb 9; 160:(3):386-8
http://www.cmaj.ca/cgi/reprint/160/3/386
HSL6872
Mandelkern M.
Manufacturer support and outcome.
J Clin Psychiatry 1999 Feb; 60:(2):122-3
HSL6888
Advertising of antibacterials
Health Skepticism 1999 Feb; 2:(2):1-5
HSL8094
Troy T.
Clinical independence meets demands of government, health care users
Managed Healthcare 1999 Feb; 9:30
HSL8096
Zoeller J.
Top 200 drugs: aggressive detailing and direct-to-consumer advertising are landing new products in the top 200 rankings much sooner
American Druggist 1999 Feb; 216:41-44, 46, 48
HSL8113
West D.
United they stand: patient care providers and DTC campaigns shake on it
Pharmaceutical Executive 1999 Feb; 2:6-8
HSL2101
Greenhalgh T.
Narrative based medicine: narrative based medicine in an evidence based world.
BMJ 1999 Jan 30; 318:(7179):323-5
http://bmj.bmjjournals.com/cgi/content/full/318/7179/323
HSL6858
Hollon MF.
Direct-to-consumer marketing of prescription drugs: creating consumer demand.
JAMA 1999 Jan 27; 281:(4):382-4
http://jama.ama-assn.org/cgi/content/full/281/4/382
HSL8142
Holmer AF.
Direct-to-consumer prescription drug advertising builds bridges between patients and physicians.
JAMA 1999 Jan 27; 281:(4):380-2
http://jama.ama-assn.org/cgi/content/full/281/4/380
HSL8151
Landis NT.
Requirements for FDA-approved patient information spelled out in final rule
American Journal of Health System Pharmacy 1999 Jan 15; 56:107-108
HSL8153
Landis NT.
Community pharmacy pricing suit dismissed
American Journal of Health System Pharmacy 1999 Jan 15; 56:113
HSL2008
Zuger A.
Fever Pitch: Getting Doctors To Prescribe Is Big Business
New York Times 1999 Jan 11
HSL4751
Ravindran GD.
The physician and the pharmaceutical industry: both must keep the patient's interests at heart.
Issues Med Ethics 1999 Jan-Mar; 7:(1):21-2
HSL6886
Advertising of CCBs for hypertension
Health Skepticism 1999 Jan; 2:(1):3-4
HSL6887
Lexchin J.
Re: the promotion of Zaditen (ketotifen)
1999 Jan;
HSL8112
Gilderman A, Salas JC, Khoury-Chamoun L.
The effectiveness of an antibiotic use program.
Manag Care Interface 1999 Jan; 12:(1):73-6
HSL8118
Wechsler J.
Policy issues for 1999
Pharmaceutical Executive 1999 Jan; 19:20, 22, 26
HSL8126
Wechsler J.
Prices, patients, privacy top 1999 agenda
Pharmaceutical Technology 1999 Jan; 23:14, 16-18, 20, 22, 24, 27
HSL1896
Gaedeke RM, Tootelian DH, Sanders EE.
Value of services provided by pharmaceutical companies: perceptions of physicians and pharmaceutical sales representatives.
Health Mark Q 1999; 17:(1):23-31
HSL2045
Heuer RJ.
. Psychology of Intelligence Analysis : Center for the Study of Intelligence, US Central Intelligence Agency 1999
http://www.cia.gov/csi/books/19104/index.html
HSL2315
Dolovich L, Levine M, Tarajos R, Duku E.
Promoting optimal antibiotic therapy for otitis media using commercially sponsored evidence-based detailing: A prospective controlled trial.
Drug Information Journal 1999; 33:(4):1067-1077
http://www.findarticles.com/p/articles/mi_qa3899/is_199910/ai_n8852536#continue
HSL2327
Jones M, Greenfield S, Bradley C
A survey of the advertising of nine new drugs in the general practice literature.
Journal of Clinical Pharmacy and Therapeutics 1999; 24:451-460
http://www.blackwell-synergy.com/doi/full/10.1046/j.1365-2710.1999.00255.x
HSL6836
A farewell to sales reps
Prescrire International 1999; 8:(41):66
HSL6837
Sales representatives: a damning report by Prescrire reps monitoring network
Prescrire International 1999; 8:(41):86-89
HSL6838
Angell M, Wood AJJ.
Authors’ conflicts of interest: a disclosure and editors’ reply
New England Journal of Medicine 1999; 341:1618-1619
HSL6840
Ashraf H.
MCA reconsiders drug advertising on the web
Lancet 1999; 353:2136
HSL6842
Bradbury J.
Storm over WHO-ISH hypertension guidelines
Lancet 1999; 353:563
HSL6845
Djulbegovic B, Bennett CL, Lyman GH.
Violation of the uncertainty principle in conduct of randomized controlled trials (RCTs) of erythropoietin (EPO)
Blood 1999; 94:(supplement 1):399a
HSL6847
Donovan J.
Advertising pharmaceuticals to Australian
Australian Prescriber 1999; 22:74-75
http://www.australianprescriber.com/magazines/vol22no4/editorial.htm
HSL6848
Dorman PJ, Counsell C, Sandercock P.
Reports of randomized trials in acute stroke, 1955 to 1995:What proportions were commercially sponsored?
Stroke 1999; 30:1995-8
http://stroke.ahajournals.org/cgi/content/full/30/10/1995
HSL6851
Ford AR
A different prescription: considerations for women’s health groups contemplating funding from the pharmaceutical industry
Toronto: National Network on Environment and Women’s Health 1999
HSL6856
Herxheimer A.
Leaflets with NSAIDs do not warn users clearly—a UK survey
Pharmaceutical Journal 1999; 262:559-561
HSL6857
Hoffman JR, Wilkes M.
Direct to consumer advertising of prescription drugs: An idea whose time should not come.
BMJ 1999; 318:1301-2
http://www.bmj.com/cgi/content/full/318/7194/1301
HSL6863
Lexchin J.
Direct-to-consumer advertising: impact on patient expectations regarding disease management
Disease Management & Health Outcomes 1999; 5:273-283
HSL6864
Lexchin J.
Following the rules in marketing
Canadian Medical Association Journal 1999; 161:685-686
http://www.cma.ca/cmaj/vol-161/issue-6/letters-6.htm#4
HSL6867
Lexchin J.
To the editor
Journal of Emergency Medicine 1999; 17:905
HSL6868
Liebeskind DS, Kidwell CS, Saver JL.
Empiric evidence of publication bias affecting acute stroke clinical trials
Stroke 1999; 30:268
HSL6870
Direct-to-consumer pharmaceuticals: media trends, market leaders, market size, market growth and more
Magazine Publishers of America 1999
www.magazine.org
HSL6871
Magazines: a healthy diagnosis. Return on investment for DTC pharmaceutical advertising. A study measuring the effectiveness of allergy advertising by PERZ/HCI
Magazine Publishers of America 1999
www.magazine.org
HSL6874
Marley J.
Complaints: a personal view
Australian Prescriber 1999; 22:80
http://www.australianprescriber.com/magazines/vol22no4/complaints.htm
HSL6878
Qizilbash N, Schneider L, Farlow M, Whitehead A, Higgins J.
Meta-analysis of tacrine for Alzheimer disease: the influence of industry sponsors
JAMA 1999; 281:2287-2288
http://jama.ama-assn.org/issues/v281n24/ffull/jlt0623-7.html
HSL6879
Roberts I.
Competing interests still exist
BMJ 1999; 318:465
http://www.bmj.com/cgi/content/full/318/7181/464/a#resp3
HSL6880
Rosen P.
Response to letter to the editor
Journal of Emergency Medicine 1999; 17:905
HSL6881
Roughead EE.
The Australian Pharmaceutical Manufacturers Association Code of Conduct: guiding the promotion of prescription medicines
Australian Prescriber 1999; 22:78-80
http://www.australianprescriber.com/magazines/vol22no4/conduct.htm
HSL6883
Sansgiry S, Sharp WT, Sansgiry SS.
Consumer understanding and interpretation of printed over-the-counter drug advertisements
Journal of Pharmaceutical Marketing & Management 1999; 13:(1):15-26
Page 2 of 22 pages < 1 2 3 4 > Last ›
